{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:41:14Z","timestamp":1778866874868,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jcjo.2017.02.012","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:01:42Z","timestamp":1500508902000},"page":"468-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity"],"prefix":"10.1016","volume":"52","author":[{"given":"Anna L.","family":"Ells","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Wesolosky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April D.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick C.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander S.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2017.02.012_bib1","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1542\/peds.2012-2996","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"131","author":"Fierson","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcjo.2017.02.012_bib3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","article-title":"Final visual acuity results in the early treatment for retinopathy of prematurity study","volume":"128","author":"Good","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib4","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0161-6420(01)01017-X","article-title":"A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome","volume":"109","author":"Ng","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2017.02.012_bib5","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0161-6420(01)01015-6","article-title":"A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome","volume":"109","author":"Connolly","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2017.02.012_bib6","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.1990.03440150056025","article-title":"Cryotherapy in infants with retinopathy of prematurity","volume":"263","author":"Hindle","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.jcjo.2017.02.012_bib7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3928\/0191-3913-20030701-06","article-title":"Laser treatment of zone I prethreshold and stage 3 threshold retinopathy of prematurity","volume":"40","author":"Recsan","year":"2003","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jcjo.2017.02.012_bib8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","article-title":"Outcome of zone 1 retinopathy of prematurity","volume":"81","author":"O\u2019Keefe","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jcjo.2017.02.012_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1067\/mpa.2000.107904","article-title":"Zone I retinopathy of prematurity","volume":"4","author":"Katz","year":"2000","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2017.02.012_bib10","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","article-title":"Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes","volume":"26","author":"Kychenthal","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2017.02.012_bib11","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1073\/pnas.101113998","article-title":"Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity","volume":"98","author":"Hellstrom","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcjo.2017.02.012_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1651-2227.2002.tb00157.x","article-title":"Pathogenesis of retinopathy of prematurity","volume":"91","author":"Smith","year":"2002","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.jcjo.2017.02.012_bib13","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1016\/j.ghir.2004.03.030","article-title":"Pathogenesis of retinopathy of prematurity","volume":"14","author":"Smith","year":"2004","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.jcjo.2017.02.012_bib14","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.ophtha.2009.04.026","article-title":"Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2017.02.012_bib15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ophtha.2008.12.023","article-title":"Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2017.02.012_bib16","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2017.02.012_bib17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000338623","article-title":"Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity","volume":"3","author":"Mota","year":"2012","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2017.02.012_bib19","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.jcjo.2017.02.012_bib22","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2017.02.012_bib23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2017.02.012_bib24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-015-0001-7","article-title":"Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease","volume":"15","author":"Menke","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib26","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2017.02.012_bib27","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.earlhumdev.2012.09.019","article-title":"Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors","volume":"88","author":"Mintz-Hittner","year":"2012","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.jcjo.2017.02.012_bib28","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib29","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2017.02.012_bib30","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity","volume":"97","author":"Castellanos","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2017.02.012_bib32","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2017.02.012_bib33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2017.02.012_bib34","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ajo.2011.08.006","article-title":"Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab","volume":"153","author":"Ma","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3928\/01913913-20150216-01","article-title":"Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years","volume":"52","author":"Klufas","year":"2015","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jcjo.2017.02.012_bib38","doi-asserted-by":"crossref","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjo.2017.02.012_bib39","first-page":"1702","article-title":"Acuity card assessment of visual function in the cryotherapy for retinopathy of prematurity trial","volume":"31","author":"Dobson","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2017.02.012_bib40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3928\/1081-597X-19970701-16","article-title":"Proper method for calculating average visual acuity","volume":"13","author":"Holladay","year":"1997","journal-title":"J Refract Surg"},{"key":"10.1016\/j.jcjo.2017.02.012_bib41","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1542\/peds.2004-1180","article-title":"Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs","volume":"115","author":"Gilbert","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcjo.2017.02.012_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/org.6.2.11687","article-title":"VEGF in the nervous system","volume":"6","author":"Rosenstein","year":"2010","journal-title":"Organogenesis"},{"key":"10.1016\/j.jcjo.2017.02.012_bib43","article-title":"Plasma level of vascular endothelial growth factor in retinopathy of prematurity after intravitreal injection of bevacizumab","volume":"52","author":"Lee","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2017.02.012_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Zhou","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib45","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3109\/02713683.2013.848899","article-title":"Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration","volume":"39","author":"Gu","year":"2014","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jcjo.2017.02.012_bib46","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Opthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/cs0940395","article-title":"Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease","volume":"94","author":"Webb","year":"1998","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jcjo.2017.02.012_bib48","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2017.02.012_bib49","first-page":"2027","article-title":"Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity","volume":"9","author":"Ar\u00e1mbulo","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib50","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1167\/iovs.12-9516","article-title":"Eye size in threshold retinopathy of prematurity, based on a Danish preterm infant series: early axial eye growth, pre- and postnatal aspects","volume":"53","author":"Fledelius","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2017.02.012_bib51","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1167\/iovs.10-6798","article-title":"Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog","volume":"52","author":"Lutty","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2017.02.012_bib52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.02.012_bib53","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.jcjo.2017.02.012_bib54","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcjo.2017.02.012_bib55","doi-asserted-by":"crossref","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418216310110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418216310110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:06:17Z","timestamp":1757793977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418216310110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0008418216310110"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2017.02.012","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2017.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}